Congress Frets Over Slow Pace of Biosimilar Licensing

FDA came under fire today from members of the House of Representatives who were critical of the agency's seemingly slow pace in approving biosimilar drugs and failure to provide manufacturers with timely guidance on developing these biological products.

Article Source: